Every material Form 8-K Bio-Rad Laboratories has filed with the SEC since April 10, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bio-Rad reported third-quarter 2026 net sales of $656.4 million, up 0.5% from a year earlier, and GAAP net income of $458.6 million, compared with a loss of $341.9 million in the prior-year quarter. The GAAP net income reflects a $588.2 million gain from the change in fair market value of its equity securities, while GAAP operating results were a loss of $49.7 million, including restructuring and impairment charges. The company kept its full-year 2026 outlook unchanged.
Net sales were $656.4 million, up 0.5%; currency-neutral sales rose 0.7%, led by Clinical Diagnostics.
GAAP net income was $458.6 million, or $17.02 per diluted share, versus a loss of $341.9 million, or $12.70 per share, a year earlier.
GAAP operating loss was $49.7 million, including $77.2 million of restructuring charges and a $49.8 million impairment of purchased intangibles.
Non-GAAP diluted income per share was $2.65, up from $2.26; full-year outlook was reaffirmed.
On July 31, 2026, Bio-Rad started a restructuring plan that removes certain positions, consolidates functions and closes various facilities, with pre-tax charges estimated at $80 million to $90 million. The same day, it reported second-quarter 2026 net sales of $651.0 million, essentially flat year over year, and reaffirmed its full-year 2026 outlook. GAAP net income rose to $371.4 million mainly because of a gain on its Sartorius AG investment, while non-GAAP net income was $70.2 million, slightly below the prior year.
Restructuring plan initiated July 31, 2026; estimated pre-tax charges of $80 million to $90 million, mostly termination benefits; expected to be substantially complete by the end of fiscal 2027.
Q2 2026 net sales $651.0 million vs. $651.6 million in Q2 2025; currency-neutral sales down 1.9 percent.
GAAP diluted EPS $13.85 vs. $11.67, driven by a change in the fair market value of the Sartorius AG investment; non-GAAP diluted EPS $2.62 vs. $2.61.
Full-year 2026 outlook reaffirmed: non-GAAP currency-neutral revenue decline of about 3.0 percent to growth of about 0.5 percent; non-GAAP operating margin of about 10.0 to 12.0 percent.
Bio-Rad reported first-quarter 2026 net sales of $592.1 million, up 1.1% from a year earlier, but a $738.2 million loss from the change in fair market value of its equity securities and loan receivable led to a GAAP net loss of $527.1 million, or $19.55 per diluted share. The company also lowered its full-year 2026 non-GAAP outlook, which matters to shareholders because the currency-neutral revenue range and operating margin range both moved down.
Q1 2026 net sales were $592.1 million, up 1.1%; currency-neutral sales fell 4.2%.
GAAP net loss was $527.1 million, or $19.55 per diluted share, versus net income of $64.0 million, or $2.29, in Q1 2025.
Non-GAAP diluted earnings per share were $1.89, versus $2.54 a year earlier; free cash flow was $78.1 million.
2026 outlook: currency-neutral revenue now a decline of about 3.0% to growth of about 0.5%, versus prior growth of 0.5% to 1.5%; non-GAAP operating margin now about 10.0% to 12.0%, versus prior 12.0% to 12.5%.
At its April 21, 2026 annual meeting, Bio-Rad stockholders approved an amended 2017 Incentive Award Plan that adds 335,000 shares and extends the plan's expiration to March 18, 2036. Stockholders also elected the six nominated directors, ratified KPMG LLP as auditor for fiscal 2026, and approved executive compensation on an advisory basis. A stockholder proposal on the dual class capital structure was not approved.
Amended 2017 Incentive Award Plan approved, adding 335,000 shares and extending expiration to March 18, 2036
Dual class capital structure proposal received 1,469,297 votes for and 5,459,554 votes against, and was not approved
KPMG LLP ratified as independent auditor for the fiscal year ending December 31, 2026, with 7,037,199 votes for and 38,994 against
Bio-Rad reported fourth-quarter 2025 revenue of $693.2 million, up 3.9% from a year earlier, but its GAAP operating result was a loss of $118.9 million after a $172.8 million impairment. Non-GAAP diluted earnings per share fell to $2.51 from $2.90, while GAAP net income of $720.0 million was driven mainly by a gain on its Sartorius AG investment. The company also gave a 2026 outlook of non-GAAP currency neutral revenue growth of about 0.5% to 1.5% and a non-GAAP operating margin of about 12.0% to 12.5%.
Q4 2025 revenue was $693.2 million, up 3.9% from $667.5 million; currency neutral growth was 1.7%
GAAP loss from operations was $118.9 million, including a $172.8 million impairment; non-GAAP operating income was $83.0 million, down from $92.1 million
GAAP net income was $720.0 million, or $26.65 per diluted share, mainly from a change in the fair market value of the Sartorius AG investment; non-GAAP diluted EPS was $2.51 versus $2.90
2026 outlook: non-GAAP currency neutral revenue growth of approximately 0.5% to 1.5% and non-GAAP operating margin of approximately 12.0% to 12.5%
Bio-Rad reported third-quarter 2025 revenue of $653.0 million, up 0.5% from a year earlier but down 1.7% on a currency-neutral basis. A $495.3 million loss from the change in fair market value of its Sartorius AG investment drove a GAAP net loss of $341.9 million, or $12.70 per diluted share, compared with net income of $653.2 million a year earlier. The company kept its full-year 2025 non-GAAP outlook unchanged.
GAAP net loss of $341.9 million, or $12.70 per diluted share, versus net income of $653.2 million, or $23.34 per share, in Q3 2024
Non-GAAP net income of $60.8 million, or $2.26 per diluted share, versus $56.3 million, or $2.02 per share, a year earlier
Non-GAAP operating margin of 11.8% versus 11.3%; currency-neutral sales decreased 1.7%, with lower sales in both Life Science and Clinical Diagnostics
Full-year 2025 outlook maintained: non-GAAP currency-neutral revenue growth of approximately 0 to 1.0% and non-GAAP operating margin of approximately 12.0 to 13.0%
Bio-Rad reported second-quarter 2025 revenue of $651.6 million, up 2.1% from a year earlier. GAAP net income was $317.8 million, or $11.67 per diluted share, compared with a net loss a year earlier, mainly due to a change in the fair market value of its Sartorius AG investment. Non-GAAP net income fell to $71.0 million, or $2.61 per diluted share, from $88.3 million, or $3.11, and the company raised its non-GAAP operating margin outlook for 2025.
Q2 2025 net sales were $651.6 million, up 2.1% from $638.5 million; currency-neutral sales rose 1.0%.
GAAP net income was $317.8 million, or $11.67 per diluted share, versus a net loss of $(2,165.5) million, or $(76.26) per share, in Q2 2024.
Non-GAAP net income was $71.0 million, or $2.61 per diluted share, versus $88.3 million, or $3.11, a year earlier.
For full-year 2025, non-GAAP operating margin is now expected at approximately 12.0% to 13.0%, up from 10.0% to 12.0%; currency-neutral revenue growth is now expected at approximately 0% to 1.0%, versus a prior range of a 1.0% decline to 1.
Bio-Rad Laboratories appointed Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025, succeeding Mike Crowley, who is retiring after a 26-year career with the company. Mehta previously served as Senior Vice President at Labcorp and as Vice President and General Manager at Thermo Fisher Scientific.
Rajat Mehta becomes EVP, Global Commercial Operations, effective August 4, 2025
Mike Crowley, who announced his retirement on January 31, 2025, will no longer be an executive officer and will remain an employee until September 2025 to assist with the transition
Mehta joins from Labcorp, where he was Senior Vice President overseeing commercial operations for the West Division
Bio-Rad reported first-quarter 2025 net sales of $585.4 million, down 4.2% from a year earlier, and GAAP net income of $64.0 million, down from $383.9 million, when large investment gains boosted results. The company also lowered its full-year 2025 outlook, cutting its non-GAAP operating margin estimate to 10.0% to 12.0% from 13.0% to 13.5% and revising revenue growth to a range of a 1.0% decline to 1.5% growth. The lower outlook signals weaker expected profitability and growth for 2025.
Q1 2025 net sales were $585.4 million, down 4.2% from $610.8 million; currency-neutral sales fell 1.5%, led by Life Science.
Q1 2025 GAAP net income was $64.0 million, or $2.29 per diluted share, versus $383.9 million, or $13.45, in Q1 2024; non-GAAP diluted EPS was $2.54 versus $2.30.
Full-year 2025 non-GAAP currency-neutral revenue is now expected to range from a 1.0% decline to 1.5% growth, down from a prior estimate of 1.5% to 3.5% growth.
Estimated full-year 2025 non-GAAP operating margin was cut to 10.0% to 12.0%, from a prior expectation of 13.0% to 13.5%.
Bio-Rad reported fourth-quarter 2024 net sales of $667.5 million, down 2.0%, and income from operations of $58.4 million, down from $95.3 million a year earlier. A $976.5 million loss from changes in the fair market value of equity securities and a loan receivable, which the company said substantially contributed to the result, drove a net loss of $715.8 million, and the company also began a restructuring that it expects to cost $45 million to $50 million. Shareholders also face a pending Stilla Technologies acquisition and 2025 guidance for non-GAAP currency-neutral revenue growth of 1.5% to 3.5%.
Q4 2024 net sales were $667.5 million, down 2.0% from $681.2 million; Life Science segment sales fell 5.5% to $275.0 million.
Q4 2024 net loss was $715.8 million, or $25.57 per diluted share, versus net income of $349.7 million in Q4 2023.
Restructuring plan initiated February 7, 2025, to eliminate about 5% of the workforce, with total costs estimated at $45 million to $50 million, $30 million to $35 million of which is expected in Q1 2025.
Company made a binding offer to buy all equity interests in Stilla Technologies, a French corporation, and expects 2025 non-GAAP operating margin of 13.0% to 13.5%.
Bio-Rad reported third-quarter 2024 net sales of $649.7 million, up 2.8% from a year earlier, led by Clinical Diagnostics. GAAP net income rose to $653.2 million, mainly from a gain on its Sartorius AG investment, while non-GAAP net income fell to $56.4 million and non-GAAP operating income declined to $73.3 million. The company kept its full-year non-GAAP revenue decline outlook of 2.5 to 4.0 percent and set a non-GAAP operating margin range of 12.75 to 13.25 percent that now includes a one-time acquired in-process R&D expense.
Net sales $649.7 million vs $632.1 million a year earlier; Clinical Diagnostics up 5.6% to $388.8 million, Life Science down 1.0% to $260.9 million
GAAP net income $653.2 million, or $23.34 per diluted share, vs $106.3 million, or $3.64, in Q3 2023
Non-GAAP net income $56.4 million, or $2.01 per diluted share, vs $68.1 million, or $2.33; non-GAAP operating income $73.3 million vs $81.6 million
Full-year 2024: non-GAAP revenue expected to decline about 2.5% to 4.0% on a currency-neutral basis; non-GAAP operating margin 12.75% to 13.25%
Bio-Rad Laboratories appointed Jonathan P. DiVincenzo, formerly an executive at Labcorp, as President and Chief Operating Officer, effective September 9, 2024, replacing Andrew Last, who retires September 5, 2024. CEO Norman Schwartz keeps his role as Chief Executive Officer and Chairman and gives up the title of President.
DiVincenzo's offer letter provides a $665,000 annual base salary and a 2024 target cash bonus of 100% of eligible earnings.
Equity and sign-on terms include restricted stock units valued at $2,500,000 within sixty days of hire and a $1.3 million sign-on bonus payable by February 15, 2025.
DiVincenzo was most recently Executive Vice President and President, Central Laboratories & International at Labcorp from May 2023 to August 2024.
Bio-Rad reported second-quarter 2024 net sales of $638.5 million, down 6.3% from a year earlier, and a GAAP net loss of $2,165.5 million, driven by a change in the fair market value of its Sartorius AG investment. The company lowered its full-year 2024 outlook, now expecting non-GAAP revenue to decline 2.5% to 4.0% on a currency-neutral basis, and its board raised the buyback authorization by $500 million.
Q2 2024 net sales were $638.5 million, down 6.3% from $681.1 million; Life Science fell 16.5% and Clinical Diagnostics rose 2.1%.
GAAP net loss was $2,165.5 million, or $76.26 per diluted share, versus a loss of $39.59 per share a year earlier; non-GAAP EPS was $3.11 versus $3.00.
Full-year 2024 non-GAAP revenue outlook moved to a 2.5% to 4.0% decline from prior 1.0% to 2.5% growth; non-GAAP operating margin outlook cut to 12.0% to 13.0% from 13.5% to 14.0%.
On July 29, 2024, the board authorized up to an additional $500 million in repurchases; about $578 million was available as of July 31, 2024.
Bio-Rad reported first-quarter 2024 net sales of $610.8 million, down 9.8% from a year earlier, with Life Science sales down 25.3% and Clinical Diagnostics up 4.7%. GAAP net income rose to $383.9 million, or $13.45 per diluted share, mainly due to a $422.2 million gain on equity securities tied to its Sartorius AG holding, while non-GAAP net income fell to $65.2 million, or $2.29 per share, from $3.34 a year earlier.
Net sales $610.8 million vs. $676.8 million in Q1 2023, a 9.8% decline; Life Science down 25.3%, Clinical Diagnostics up 4.7%
Income from operations $44.7 million vs. $61.9 million; non-GAAP operating margin 9.7% vs. 12.4%
GAAP net income $383.9 million ($13.45 per diluted share) vs. $69.0 million ($2.32), driven by changes in the fair market value of Sartorius AG-related equity securities
Full-year 2024 outlook maintained: non-GAAP currency-neutral revenue growth of approximately 1.0% to 2.5% and non-GAAP operating margin of approximately 13.5% to 14.0%
Bio-Rad Laboratories said Simon May, Executive Vice President and President of the Life Science Group and a named executive officer, will resign effective May 1, 2024, to pursue another opportunity. James J. Barry, the company's Senior Vice President of Global Manufacturing, will take over that role on the same date. The filing also reports annual meeting votes, including stockholder approval of an amended 2017 Incentive Award Plan, but contains no financial results.
Simon May resigns as EVP and President, Life Science Group, effective May 1, 2024
James J. Barry appointed EVP and President, Life Science Group, effective May 1, 2024 (appointed April 24, 2024)
Stockholders approved the amended 2017 Incentive Award Plan at the April 23, 2024 annual meeting; plan expiration extended to February 9, 2034
Bio-Rad Laboratories' Executive Vice President and Chief Operating Officer, Dr. Andrew Last, notified the company on April 10, 2024 that he plans to retire by early September 2024. He will stay in his current role while Bio-Rad searches for a successor, which the company says is intended to ensure a smooth transition.
Dr. Andrew Last, EVP and Chief Operating Officer, intends to retire by early September 2024
Dr. Last will remain in his current position while the company searches for a successor
Dr. Last joined Bio-Rad in April 2019; CEO Norman Schwartz credited him with cost structure, core process and supply chain improvements
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bio-Rad Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →